0
Summaries for Patients |

Tamoxifen for the Treatment of Retroperitoneal Fibrosis FREE

[+] Article and Author Information

The summary below is from the full report titled “Brief Communication: Tamoxifen Therapy for Nonmalignant Retroperitoneal Fibrosis.” It is in the 17 January 2006 issue of Annals of Internal Medicine (volume 144, pages 101-106). The authors are E.F.H. van Bommel, T.R. Hendriksz, A.W.L.C. Huiskes, and A.G.M. Zeegers.


Ann Intern Med. 2006;144(2):I-51. doi:10.7326/0003-4819-144-2-200601170-00002
Text Size: A A A

What is the problem and what is known about it so far?

Retroperitoneal fibrosis (RF) is a rare condition in which hard scar tissue develops behind the abdomen. It develops because of cancer, inflammation, or for no apparent reason. It first causes symptoms of dull low back or abdominal pain. As it progresses, the scar tissue may press on the kidneys and blood vessels and cause bloody urine, leg pain, and blood clots. Treatment of RF is surgical removal of the tissue. However, because the tissue is extremely hard, it may not easily separate from organs and vessels. As a result, complete surgical removal is often impossible. For this reason, there is great interest in finding drugs to help treat RF. Tamoxifen is a drug that blocks the effects of the hormone estrogen. Reports suggest that tamoxifen is useful for treating RF. This information, however, comes from individual patients treated and monitored differently by different doctors. To be more sure that tamoxifen is safe and effective in treating RF, it would be helpful to have information from a larger group of patients who were treated and monitored similarly.

Why did the researchers do this particular study?

To see whether tamoxifen is safe and effective in a large group of patients with RF.

Who was studied?

19 patients with RF who were seen over 6 years at a Dutch medical center. Most of the patients were older men.

How was the study done?

The researchers assessed the patients' symptoms. They also took blood tests to look for signs of inflammation and measured the size of the scar tissue using computed tomography (CT) scans. They then prescribed tamoxifen for the patients and measured changes in symptoms, signs of inflammation, and size of scar tissue every few months while the patients were taking the drug.

What did the researchers find?

Tamoxifen helped 14 of the 19 patients. Symptoms improved within weeks, and within months signs of inflammation decreased and the scar tissue shrunk. Retroperitoneal fibrosis returned in 1 patient after the drug was withdrawn but improved when therapy was started again. Of the 5 patients who did not improve while taking tamoxifen, 3 did well on a combination of drugs that suppress the immune system. None of the patients experienced any serious side effects.

What were the limitations of the study?

The researchers did not compare tamoxifen with surgery or other drugs. Therefore, the findings do not imply that tamoxifen is better than other treatments. The researchers studied the patients for only 2 years. Many patients with RF will take the drug for longer periods. It is possible that tamoxifen may be less safe or effective when taken over this longer time. Also, the findings did not provide information about why tamoxifen may be effective for RF.

What are the implications of the study?

Tamoxifen can be considered an option for the treatment of patients with RF. It is not yet known how long the drug should be taken to be most effective or how safe and effective it is over long periods of time and compared with other treatments.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)